PETHEMA Foundation: Multiple Myeloma trials

The registry lists 30 Multiple Myeloma studies with PETHEMA Foundation as lead sponsor. 1 are open to participants now and 0 have results posted.

Phase 1 4Phase 2 16Phase 3 8Phase 4 2No phase 3(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Ciltacabtagene Autoleucel in High-Risk Smoldering Multiple MyelomaRecruitingNCT06574126Phase 2
• Study of Elranatamab for Relapsed or Refractory Myeloma in Patients Previously Exposed to Three-drug ClassesActive, not recruitingNCT06282978Phase 2
• Iberdomide-dexamethasone Alone or in Combination With Standard MM Treatment Regimens in Transplant Ineligible Newly Diagnosed Patients.Active, not recruitingNCT05527340Phase 2
• Retrospective Study of the Use of Belantamab Mafodotin (Blenrep®) in Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) in Spain.Status unknownNCT05297240
• Evaluation of Maintenance With Bortezomib Plus Daratumumab (V-Dara) After Induction With Bortezomib, Melphalan, Prednisone Plus Daratumumab (VMP-Dara) in Newly Diagnosed Multiple Myeloma (MM) Patients Non-eligible for autoSCTStatus unknownNCT05218603
• Study of Belantamab Mafodotin in Combination With Kd for the Treatment of Relapsed Myeloma Patients, Refractory to LenalidomideActive, not recruitingNCT05060627Phase 1/2
• Belantamab Mafodotin in Newly Diagnosed Transplant Eligible Multiple Myeloma PatientsActive, not recruitingNCT04802356Phase 2
• Treatment for Elderly Fit Newly Diagnosed Multiple Myeloma Patients Aged Between 65 and 80 YearsActive, not recruitingNCT03742297Phase 3
• SELIBORDARA: Selinexor, Bortezomib and Daratumumab in Multiple MyelomaActive, not recruitingNCT03589222Phase 2
• Retrospective Viability Study of the PETHEMA-POMCIDEX Clinical Practice Guidelines for the Treatment of Patients With Relapsed and Refractory Multiple Myeloma (RRMM)CompletedNCT03477643
• Carfilzomib, Cyclophosphamide, Dexamethasone in Multiple MyelomaStatus unknownNCT03336073Phase 2
• Nivolumab Role in the Treatment of Patients With Refractory or Relapse Multiple MyelomaTerminatedNCT03023527Phase 1
• Pembrolizumab (MK-3475) in MM Patients With Residual DiseaseCompletedNCT02636010Phase 2
• GEM-CLARIDEX: Ld vs BiRdStatus unknownNCT02575144Phase 3
• Carfilzomib in Treatment Patients Under 65 Years With High Risk Smoldering Multiple MyelomaActive, not recruitingNCT02415413Phase 2
• Trial Studying Maintenance Treatment With Lenalidomide and Dexamethasone Versus Lenalidomide, Dexamethasone and MLN9708 After Autologous Hematopoietic Stem Cell Transplantation in Patients With Newly-diagnosed Symptomatic Multiple MyelomaCompletedNCT02406144Phase 3
• Filanesib (ARRY-520) in Combination With Pomalidomide and Dexamethasone for Relapsed/Refractory (R/R) Multiple Myeloma (MM) PatientsCompletedNCT02384083Phase 1/2
• Bortezomib (Velcade®), Lenalidomide (Revlimid®) and IV Busulfan (Busilvex®) in Patients Under 65 Years OldCompletedNCT01916252Phase 3
• Bendamustine, Bortezomib (Velcade ®) and Prednisone (BVP) in Patients Newly Diagnosed Multiple MyelomaCompletedNCT01376401Phase 2
• Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd) Versus Alternating Velcade/Melphalan/Prednisone (MPV) With Revlimid/Low Dose DexamethasoneCompletedNCT01237249Phase 2
• Zoledronic Acid in Patients With Multiple Myeloma and Asymptomatic Biochemical RelapseCompletedNCT01087008Phase 4
• Study of Induction Treatment With Velcade and Dexamethasone for Previously Untreated Patients With Multiple Myeloma and Renal FailureCompletedNCT01084837Phase 2
• Bortezomib/Adriamycine/Melfalan/Prednisone (VAMP)/Thalidomide/Cyclophosphamide/Dexamethasone (TaCyDex) or Bortezomib/Melfalan/Prednisone (V-MP)/TaCyDex) in Refractary or Relapsed Multiple MyelomaCompletedNCT00652041Phase 4
• MINIALO-VELCADE2005: A Study of Bortezomib (Velcade) Treated Multiple Myeloma Patients Pre and Post Allogeneic Haematopoietic Progenitor Cell Transplant With no Myeloablative ConditioningCompletedNCT00564200Phase 2
• Pethema Multiple Myeloma 2000CompletedNCT00560053Phase 3
• QUIREDEX: Revlimid (Lenalidomide) and Dexamethasone (ReDex) Treatment Versus Observation in Patients With Smoldering Multiple Myeloma With High Risk of ProgressionCompletedNCT00480363Phase 3
• GEM05 for Patients With Multiple Myeloma Under 65 YearsCompletedNCT00461747Phase 3
• GEM05 for Patients With Multiple Myeloma More Than 65 Years OldCompletedNCT00443235Phase 3
• VELCADEXA: Velcade and Dexamethasone in Multiple MyelomaCompletedNCT00391157Phase 2
• Velcade-Melphalan-Prednisone in Older Untreated Multiple Myeloma Patients.CompletedNCT00388635Phase 1/2